DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 207 filers reported holding DENALI THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $752,706 | -30.1% | 36,486 | 0.0% | 0.25% | -27.5% |
| Q2 2023 | $1,076,702 | +28.1% | 36,486 | 0.0% | 0.34% | +23.0% |
| Q1 2023 | $840,637 | +8.1% | 36,486 | +30.5% | 0.28% | +4.5% |
| Q4 2022 | $777,762 | -9.4% | 27,967 | 0.0% | 0.27% | -15.8% |
| Q3 2022 | $858,000 | +4.3% | 27,967 | 0.0% | 0.32% | +13.7% |
| Q2 2022 | $823,000 | -8.6% | 27,967 | 0.0% | 0.28% | +6.9% |
| Q1 2022 | $900,000 | -27.8% | 27,967 | 0.0% | 0.26% | -26.1% |
| Q4 2021 | $1,247,000 | -11.6% | 27,967 | 0.0% | 0.35% | -18.3% |
| Q3 2021 | $1,411,000 | -7.0% | 27,967 | +44.6% | 0.43% | -7.3% |
| Q2 2021 | $1,518,000 | +8.8% | 19,346 | -20.8% | 0.46% | +1.1% |
| Q1 2021 | $1,395,000 | -36.3% | 24,438 | -6.6% | 0.46% | -42.9% |
| Q4 2020 | $2,190,000 | +188.9% | 26,151 | +23.6% | 0.81% | +147.2% |
| Q3 2020 | $758,000 | +29.8% | 21,151 | -12.4% | 0.33% | +19.0% |
| Q2 2020 | $584,000 | +38.1% | 24,151 | 0.0% | 0.27% | +17.1% |
| Q1 2020 | $423,000 | – | 24,151 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |